Biotech Shares Surge 72% with $8 Million Transaction, Yet This Is Why a Fund Remains Optimistic

NodeGuardian

2026-03-22 00:08:07

Abstract generation in progress

Kynam Capital Management sold 469,041 shares of Syndax Pharmaceuticals (NASDAQ:SNDX) for approximately $8.18 million, yet the fund’s overall holdings in Syndax increased by $38.07 million. Despite the transaction, Syndax still constitutes over 10% of Kynam’s assets, indicating continued confidence in the company, which has seen a 72% increase in share price over the past year due to successful therapy launches. The sale is viewed as a tactical rebalancing rather than a change in investment outlook, typical for firms balancing rapid growth with ongoing R&D expenses.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes